Vanguard Group
TCRX icon

Vanguard Group’s TScan Therapeutics TCRX Stock Holding History

Vanguard Group’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.48M Buy
2,475,733
+157,817
+7% +$228K ﹤0.01% 3491
2025
Q3 		$4.22M Buy
2,317,916
+168,540
+8% +$299K ﹤0.01% 3331
2025
Q2 		$3.12M Sell
2,149,376
-207,370
-9% -$300K ﹤0.01% 3374
2025
Q1 		$3.25M Sell
2,356,746
-25,787
-1% -$55.8K ﹤0.01% 3325
2024
Q4 		$7.24M Buy
2,382,533
+35,639
+2% +$162K ﹤0.01% 3116
2024
Q3 		$11.7M Buy
2,346,894
+213,281
+10% +$1.29M ﹤0.01% 2876
2024
Q2 		$12.5M Buy
2,133,613
+325,461
+18% +$2.56M ﹤0.01% 2792
2024
Q1 		$14.4M Buy
1,808,152
+20,000
+1% +$126K ﹤0.01% 2764
2023
Q4 		$10.4M Buy
1,788,152
+35,558
+2% +$163K ﹤0.01% 2924
2023
Q3 		$4.49M Buy
1,752,594
+393,305
+29% +$918K ﹤0.01% 3296
2023
Q2 		$3.4M Buy
1,359,289
+1,062,464
+358% +$2.85M ﹤0.01% 3471
2023
Q1 		$623K Buy
296,825
+30,771
+12% +$73.1K ﹤0.01% 4058
2022
Q4 		$412K Buy
266,054
+8,638
+3% +$21.2K ﹤0.01% 4154
2022
Q3 		$785K Buy
257,416
+31,352
+14% +$103K ﹤0.01% 4073
2022
Q2 		$711K Sell
226,064
-865
-0.4% -$2.37K ﹤0.01% 4192
2022
Q1 		$636K Sell
226,929
-11,085
-5% -$47.9K ﹤0.01% 4334
2021
Q4 		$1.07M Sell
238,014
-206,880
-47% -$1.49M ﹤0.01% 4251
2021
Q3 		$3.71M Buy
+444,894
New +$4.13M ﹤0.01% 3824

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's TCRX Position: Q4 2025 in Review

Vanguard Group increased its TScan Therapeutics (TCRX) stake by 6.8% in Q4 2025, buying an estimated $228K and bringing the position to 2,475,733 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3491.

Vanguard Group first reported a position in TCRX in Q3 2021 and has held it in 18 quarters since. The position peaked at $14.4M in Q1 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Vanguard Group held 2,475,733 shares of TScan Therapeutics worth $2.48M as of Q4 2025.
  • Vanguard Group bought 157,817 TScan Therapeutics shares in Q4 2025, an estimated $228K.
  • TScan Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3491 holding.
  • Vanguard Group first reported a position in TScan Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's TScan Therapeutics position peaked at $14.4M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.